Interested in learning more?
For clinical trial information, please email [email protected]
For medical inquiries in the US, please email [email protected]
For medical inquiries in the US, please email [email protected]
FIREFLY-2:
Tovorafenib, an investigational, oral, pan-RAF inhibitor versus standard of care chemotherapy being studied in pediatric patients with RAF-altered low-grade glioma requiring front-line systemic therapy
FIREFLY-1:
Tovorafenib, an investigational, oral, pan-RAF inhibitor being studied in pediatric patients with recurrent or progressive low-grade glioma and advanced solid tumors with RAF alterations